Biomea Fusion

NSQ:BMEA · US09077A1060

BiotechnologySmall

360° View

Value19

Price/Sales—

Price/Earnings10

Price/Book78

Dividend Yield1

Growth14

Revenue Growth—

Profit Growth64

Capital Growth4

TSR 52w4

Safety47

Leverage43

Liquidity88

Refinancing15

Combined16

Sentiment1

Analyst Opinions15

Pro Holdings33

Opinion Changes36

Market Pulse1

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2017

Employees64

Websitebiomeafusion.com

ISINUS09077A1060

Last UpdateApr 2, 2026

Index & Theme

DiabetesEndocrinologyPharmacovigilanceObesityBiotechnologyHealth CareScience and Engineering

Description

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases. Leveraging the company’s extensive expertise in c…

Analysis

Biomea Fusion's 360° View rank of 9 places it among the weakest overall — better than 9% of its true peers.

It's lagging on growth (14) and expensive versus peers (19). On safety it is carrying more balance-sheet risk (47), and the market shows skeptical sentiment (1). Taken together, its Combined rank of 16 reads as among the weakest overall.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Biomea Fusion with its peers

Syndax Pharmaceuticals

NSQ:SNDX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Acrivon Therapeutics

NMQ:ACRV

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Immuneering

NMQ:IMRX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

BIOAGE Labs

NSQ:BIOA

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

BridgeBio Oncology Therapeutics

NMQ:BBOT

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tharimmune

NAQ:THAR

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →